相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Immunology
Lennard Y. W. Lee et al.
Summary: The study found that the infectivity of SARS-CoV-2 varies with case viral load, contact event type, and age. Those with high viral loads are the most infectious. The B.1.1.7 variant increases transmission by 50%. The best performing LFDs can detect most infectious cases.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
N. Kojima et al.
Summary: Both supervised oral fluid and nasal swab specimens performed similarly to clinician-collected nasopharyngeal swab specimens in detecting SARS-CoV-2, and none of the positive participants were detected using any sample type.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Wan Ni Chia et al.
Summary: The study investigated the dynamics of neutralising antibody response in patients who have recovered from COVID-19, finding great variations and suggesting that predicting immune longevity can only be accurately determined at the individual level. The findings emphasize the importance of public health and social measures in the ongoing pandemic outbreak response, and may have implications for the longevity of immunity after vaccination.
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.
Article
Public, Environmental & Occupational Health
Koen B. Pouwels et al.
Summary: This study in England found significant changes in the number of individuals testing positive for SARS-CoV-2 and risk factors for positivity over time from April to November 2020. Important risk factors for testing positive varied between the first and second waves, with age being a key driver of increased positivity rates in the second wave. Continued monitoring for SARS-CoV-2 in the community will be important for managing the COVID-19 pandemic moving forwards.
LANCET PUBLIC HEALTH
(2021)
Article
Multidisciplinary Sciences
Dami A. Collier et al.
Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Nicholas G. Davies et al.
Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.
Article
Multidisciplinary Sciences
Chadi M. Saad-Roy et al.
Summary: Given vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels to SARS-CoV-2. While focusing on one dose may decrease infections in the short term, the long-term outcomes depend on the relative immune robustness of this approach. Under conditions of partial population immunity, a one-dose policy may increase the potential for antigenic evolution.
Article
Immunology
A. Chaillon et al.
Summary: The study suggests that the rapid rise of the B.1.1.7 Variant of Concern most likely occurred through global dispersal rather than convergent evolution from multiple sources.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Christian Holm Hansen et al.
Summary: The study investigated the protection against SARS-CoV-2 reinfection, with results showing an 80.5% protection rate for individuals previously infected. Even in the population aged 65 years and older, the protection rate against reinfection reached 47.1%, with no significant differences observed by gender or time since infection.
Article
Medicine, General & Internal
Victoria Jane Hall et al.
Summary: The study aimed to determine the factors associated with vaccine coverage for two COVID-19 vaccines in the UK and to document the vaccine effectiveness of the BNT162b2 mRNA vaccine among healthcare workers. Results showed that the vaccine can prevent both symptomatic and asymptomatic infections in working-age adults, with a vaccine effectiveness of 70% after the first dose and 85% after the second dose.
Article
Medicine, General & Internal
Katherine R. W. Emary et al.
Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.
Article
Multidisciplinary Sciences
Nicholas G. Davies et al.
Summary: Studies have shown that the SARS-CoV-2 B.1.1.7 lineage is more transmissible and may cause more severe illness compared to pre-existing variants.
Article
Medicine, General & Internal
Jamie Lopez Bernal et al.
Summary: This study estimated the real-world effectiveness of Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed COVID-19 symptoms, hospital admissions, and deaths. The vaccines showed significant reduction in symptomatic COVID-19 among older adults and further protection against severe disease. Both vaccines demonstrated similar effects and protection was maintained for over 6 weeks.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Public, Environmental & Occupational Health
Mark G. Thompson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
